Valerius T - Search Results

1

An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.

Wirt T, Rosskopf S, Rösner T, Eichholz KM, Kahrs A, Lutz S, Kretschmer A, Valerius T, Klausz K, Otte A, Gramatzki M, Peipp M, Kellner C. Wirt T, et al. Among authors: valerius t. Transfus Med Hemother. 2017 Sep;44(5):292-300. doi: 10.1159/000479978. Epub 2017 Sep 11. Transfus Med Hemother. 2017. PMID: 29070974 Free PMC article.

2

Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor.

Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR, Platzer E. Repp R, et al. Among authors: valerius t. Blood. 1991 Aug 15;78(4):885-9. Blood. 1991. PMID: 1714327 Free article.

3

Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy.

Valerius T, Repp R, de Wit TP, Berthold S, Platzer E, Kalden JR, Gramatzki M, van de Winkel JG. Valerius T, et al. Blood. 1993 Aug 1;82(3):931-9. Blood. 1993. PMID: 7687898 Free article.

4

HLA class II antibodies recruit G-CSF activated neutrophils for treatment of B cell malignancies.

Valerius T, Elsässer D, Repp R, Van de Winkel JG, Gramatzki M, Glennie M. Valerius T, et al. Leuk Lymphoma. 1997 Jul;26(3-4):261-9. doi: 10.3109/10428199709051775. Leuk Lymphoma. 1997. PMID: 9322888 Review.

5

FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.

Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, van de Winkel JG. Valerius T, et al. Blood. 1997 Dec 1;90(11):4485-92. Blood. 1997. PMID: 9373259 Free article.

6

[Antibodies as specific tumor therapy agents. Wishful thinking or reality?].

Gramatzki M, Valerius T. Gramatzki M, et al. Among authors: valerius t. Internist (Berl). 1997 Nov;38(11):1055-62. doi: 10.1007/s001080050117. Internist (Berl). 1997. PMID: 9453954 Review. German. No abstract available.

7

Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.

Würflein D, Dechant M, Stockmeyer B, Tutt AL, Hu P, Repp R, Kalden JR, van de Winkel JG, Epstein AL, Valerius T, Glennie M, Gramatzki M. Würflein D, et al. Among authors: valerius t. Cancer Res. 1998 Jul 15;58(14):3051-8. Cancer Res. 1998. PMID: 9679970

8

Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies.

Stockmeyer B, Elsässer D, Dechant M, Repp R, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T. Stockmeyer B, et al. Among authors: valerius t. J Immunol Methods. 2001 Feb 1;248(1-2):103-11. doi: 10.1016/s0022-1759(00)00346-x. J Immunol Methods. 2001. PMID: 11223072

9

Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?

Stadick H, Stockmeyer B, Kühn R, Schrott KM, Kalden JR, Glennie MJ, van de Winkel JG, Gramatzki M, Valerius T, Elsässer D. Stadick H, et al. Among authors: valerius t. J Urol. 2002 Feb;167(2 Pt 1):707-12. doi: 10.1016/S0022-5347(01)69131-6. J Urol. 2002. PMID: 11792958

10

Bispecific antibodies targeting cancer cells.

Peipp M, Valerius T. Peipp M, et al. Among authors: valerius t. Biochem Soc Trans. 2002 Aug;30(4):507-11. doi: 10.1042/bst0300507. Biochem Soc Trans. 2002. PMID: 12196124 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

180 results

Search Page

Filters